TapewireFind a company

person · Reporting owner

Huber Martin H. Jr.

Disclosed activity across 5 companies

Tapewire entity
44725
SEC CIK
0001653276

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ACTUATE THERAPEUTICS, INC.ACTU · Entity 7370DirectorMay 21, 2026May 22, 2026
Syndax Pharmaceuticals IncSNDX · Entity 4578DirectorFebruary 04, 2026February 06, 2026
Xilio Therapeutics, Inc.XLO · Entity 7122PRESIDENT AND HEAD OF R&DAugust 16, 2023August 19, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACTUATE THERAPEUTICS, INC.

Report date May 21, 2026 · Filed May 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.42 · Expires 2036-05-21Direct15,000 Reported balance After 2026-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-21 · Grant · Acquired 15,000 · Balance 15,000

F1: Options will vest in full on the anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Options will vest in full on the anniversary of the grant date.

Syndax Pharmaceuticals Inc

Report date February 04, 2026 · Filed February 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect103,000 Reported balance After 2026-02-04 transaction · row 1
1 source row

Row 1 · 2026-02-04 · Grant · Acquired 24,000 · Balance 103,000

F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Filing footnotes · ownership attribution and instrument terms

F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Xilio Therapeutics, Inc.

Report date August 16, 2023 · Filed August 19, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2033-08-15Direct136,500 Reported balance After 2023-08-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-08-16 · Grant · Acquired 136,500 · Balance 136,500

F1: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Mersana Therapeutics, Inc.

Report date January 06, 2026 · Filed January 06, 2026

Section 16 reporting ended · disclosed 2026-01-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2026-01-06 transaction · row 1
1 source row

Row 1 · 2026-01-06 · Other · Disposed 9,573 · Balance 0

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01Direct0 Reported balance After 2026-01-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-01-06 · Disposition to issuer · Disposed 5,938 · Balance 0

F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01Direct0 Reported balance After 2026-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-01-06 · Disposition to issuer · Disposed 26,713 · Balance 0

F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $214.25Direct0 Reported balance After 2026-01-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-01-06 · Disposition to issuer · Disposed 1,923 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $527.25Direct0 Reported balance After 2026-01-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-01-06 · Disposition to issuer · Disposed 99 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $372.50Direct0 Reported balance After 2026-01-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-01-06 · Disposition to issuer · Disposed 1,002 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.00Direct0 Reported balance After 2026-01-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-01-06 · Disposition to issuer · Disposed 407 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.50Direct0 Reported balance After 2026-01-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2026-01-06 · Disposition to issuer · Disposed 1,800 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.25Direct0 Reported balance After 2026-01-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2026-01-06 · Disposition to issuer · Disposed 135 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $216.00Direct0 Reported balance After 2026-01-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2026-01-06 · Disposition to issuer · Disposed 734 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.50Direct0 Reported balance After 2026-01-06 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2026-01-06 · Disposition to issuer · Disposed 179 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.00Direct0 Reported balance After 2026-01-06 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2026-01-06 · Disposition to issuer · Disposed 12,121 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.00Direct0 Reported balance After 2026-01-06 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2026-01-06 · Disposition to issuer · Disposed 27,878 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.50Direct0 Reported balance After 2026-01-06 transaction · row 14 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 14 · 2026-01-06 · Disposition to issuer · Disposed 364 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.50Direct0 Reported balance After 2026-01-06 transaction · row 15 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 15 · 2026-01-06 · Disposition to issuer · Disposed 497 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.50Direct0 Reported balance After 2026-01-06 transaction · row 16 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 16 · 2026-01-06 · Disposition to issuer · Disposed 7,467 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct0 Reported balance After 2026-01-06 transaction · row 17 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 17 · 2026-01-06 · Disposition to issuer · Disposed 13,340 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct0 Reported balance After 2026-01-06 transaction · row 18 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 18 · 2026-01-06 · Disposition to issuer · Disposed 1,328 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct0 Reported balance After 2026-01-06 transaction · row 19 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 19 · 2026-01-06 · Disposition to issuer · Disposed 7,256 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

TESARO, Inc.

Report date January 22, 2019 · Filed January 22, 2019

Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2019-01-22 transaction · row 1
1 source row

Row 1 · 2019-01-22 · Other · Disposed 12,206 · Balance 0

F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2019-01-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2019-01-22 · Disposition to issuer · Disposed 1,250 · Balance 0

F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2019-01-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2019-01-22 · Disposition to issuer · Disposed 8,750 · Balance 0

F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2019-01-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2019-01-22 · Disposition to issuer · Disposed 4,447 · Balance 0

F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2019-01-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2019-01-22 · Disposition to issuer · Disposed 22,727 · Balance 0

F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.14 · Expires 2025-09-21Direct0 Reported balance After 2019-01-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2019-01-22 · Disposition to issuer · Disposed 75,000 · Balance 0

F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.39 · Expires 2026-03-01Direct0 Reported balance After 2019-01-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2019-01-22 · Disposition to issuer · Disposed 35,000 · Balance 0

F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $178.95 · Expires 2027-03-01Direct0 Reported balance After 2019-01-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2019-01-22 · Disposition to issuer · Disposed 10,782 · Balance 0

F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.84 · Expires 2028-03-01Direct0 Reported balance After 2019-01-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2019-01-22 · Disposition to issuer · Disposed 39,942 · Balance 0

F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Filing footnotes · ownership attribution and instrument terms

F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").

F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 21, 2026 Filed May 22, 2026 20:03 UTC ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 GrantStock Options · Derivative 15,000 $0.00 Strike: $2.42 $0.00
Disclosure

SEC source: 0001683168-26-004243 · ownership.xml · derivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2036-05-21

F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 21:55 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantCommon Stock 24,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-041344 · ownership.xml · nonDerivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,000

F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerRestricted Stock Units · Derivative 7,256 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 19

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,256 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerRestricted Stock Units · Derivative 1,328 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 18

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,328 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerRestricted Stock Units · Derivative 13,340 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 17

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,340 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 7,467 Not disclosed Strike: $75.50 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 16

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,467 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 497 Not disclosed Strike: $75.50 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 15

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 497 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 364 Not disclosed Strike: $31.50 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 14

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 364 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 27,878 Not disclosed Strike: $33.00 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 13

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,878 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 12,121 Not disclosed Strike: $33.00 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 12

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,121 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 179 Not disclosed Strike: $85.50 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 11

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 179 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 734 Not disclosed Strike: $216.00 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 10

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 734 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 135 Not disclosed Strike: $106.25 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 9

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 135 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 1,800 Not disclosed Strike: $90.50 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 8

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,800 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 407 Not disclosed Strike: $161.00 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 7

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 407 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 1,002 Not disclosed Strike: $372.50 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 6

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,002 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 99 Not disclosed Strike: $527.25 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 5

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 99 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 1,923 Not disclosed Strike: $214.25 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 4

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,923 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 26,713 Not disclosed Strike: $16.01 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 3

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,713 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Disposition to issuerStock Option (right to buy) · Derivative 5,938 Not disclosed Strike: $16.01 Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 2

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,938 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:47 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 OtherCommon Stock 9,573 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · nonDerivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),

F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),

F2 · price: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 20:26 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 SaleCommon Stock 2,012 $7.31 $14,707.72
Disclosure

SEC source: 0001104659-25-090026 · tm2526132-1_4seq1.xml · nonDerivative · entry 2

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,572

F3 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.22 to $7.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 20:26 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Exercise / conversionRestricted Stock Unit · Derivative 6,670 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-090026 · tm2526132-1_4seq1.xml · derivative · entry 3

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,340

Underlying: Common Stock · 20,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025.

F6 · derivative.exercise_date: 25% of the total number of RSUs granted vested on September 11, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years.

F6 · derivative.expiration_date: 25% of the total number of RSUs granted vested on September 11, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 20:26 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Exercise / conversionCommon Stock 6,670 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-090026 · tm2526132-1_4seq1.xml · nonDerivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,584

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on September 11, 2023.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025.

Read SEC document
May 19, 2025 Filed May 19, 2025 20:02 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 PurchaseCommon Stock 5,000 $8.99 $44,950.00
Disclosure

SEC source: 0000950170-25-074297 · ownership.xml · nonDerivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,000

Read SEC document
February 05, 2025 Filed Feb 7, 2025 21:34 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantCommon Stock 25,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-016351 · ownership.xml · nonDerivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,000

F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Read SEC document
January 16, 2025 Filed Jan 18, 2025 00:21 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 SaleCommon Stock 4,514 $0.58 $2,618.12
Disclosure

SEC source: 0001104659-25-004593 · tm253733-4_4seq1.xml · nonDerivative · entry 2

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 122,875

F2 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
January 15, 2025 Filed Jan 18, 2025 00:21 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantRestricted Stock Unit · Derivative 181,400 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-004593 · tm253733-4_4seq1.xml · derivative · entry 5

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 181,400

Underlying: Common Stock · 181,400 shares

Expires not disclosed

F4 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer.

F7 · derivative.exercise_date: The RSUs shall vest in equal annual installments over four years from the date of grant.

F7 · derivative.expiration_date: The RSUs shall vest in equal annual installments over four years from the date of grant.

Read SEC document
January 15, 2025 Filed Jan 18, 2025 00:21 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantStock Option (Right to Buy) · Derivative 816,300 $0.00 Strike: $0.64 $0.00
Disclosure

SEC source: 0001104659-25-004593 · tm253733-4_4seq1.xml · derivative · entry 4

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 816,300

Underlying: Common Stock · 816,300 shares

Expires 2035-01-14

F6 · derivative.exercise_date: The option shall vest in equal quarterly installments over four years from the date of grant.

Read SEC document
January 15, 2025 Filed Jan 18, 2025 00:21 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Exercise / conversionRestricted Stock Unit · Derivative 11,062 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-004593 · tm253733-4_4seq1.xml · derivative · entry 3

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,188

Underlying: Common Stock · 11,062 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer.

F5 · derivative.exercise_date: 25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years.

F5 · derivative.expiration_date: 25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years.

Read SEC document
January 15, 2025 Filed Jan 18, 2025 00:21 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Exercise / conversionCommon Stock 11,062 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-004593 · tm253733-4_4seq1.xml · nonDerivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 127,389

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 15, 2024.

Read SEC document
September 12, 2024 Filed Sep 13, 2024 21:08 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 SaleCommon Stock 50,423 $1.76 $88,744.48
Disclosure

SEC source: 0001104659-24-099855 · tm2424033-2_4seq1.xml · nonDerivative · entry 2

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,327

F3 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.735 to $1.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
September 11, 2024 Filed Sep 13, 2024 21:08 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Exercise / conversionRestricted Stock Unit · Derivative 166,750 $0.00 $0.00
Disclosure

SEC source: 0001104659-24-099855 · tm2424033-2_4seq1.xml · derivative · entry 3

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 500,250

Underlying: Common Stock · 166,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer.

F6 · derivative.exercise_date: 25% of the RSUs granted vested on September 11, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years.

F6 · derivative.expiration_date: 25% of the RSUs granted vested on September 11, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years.

Read SEC document
September 11, 2024 Filed Sep 13, 2024 21:08 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 Exercise / conversionCommon Stock 166,750 $0.00 $0.00
Disclosure

SEC source: 0001104659-24-099855 · tm2424033-2_4seq1.xml · nonDerivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 166,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on September 11, 2023.

F2 · balance_after: On June 12, 2023, the Reporting Person filed a Form 4 reporting the award of a RSU award representing the right to receive 14,467 shares of common stock of the Issuer on June 8, 2023. Such RSU award was subsequently rescinded in connection with the Reporting Person's appointment as president and chief executive officer effective in September 2023 and as a result was cancelled for no value. The amount of securities beneficially owned reported in this Form 4 reflects an adjustment in the number of shares held by the Reporting Person, reflecting the cancellation of the June 8, 2023 RSU award for no value.

Read SEC document
February 07, 2024 Filed Feb 9, 2024 21:04 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantCommon Stock 17,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-24-001220 · primarydocument.xml · nonDerivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,000

F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Read SEC document
January 15, 2024 Filed Jan 17, 2024 22:19 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantRestricted Stock Unit · Derivative 44,250 $0.00 $0.00
Disclosure

SEC source: 0001104659-24-004545 · tm243529-4_4seq1.xml · derivative · entry 2

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 44,250 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock of the Issuer.

F3 · derivative.exercise_date: The RSUs shall vest in equal annual installments over four years from the date of grant.

F3 · derivative.expiration_date: The RSUs shall vest in equal annual installments over four years from the date of grant.

Read SEC document
January 15, 2024 Filed Jan 17, 2024 22:19 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantStock Option (Right to Buy) · Derivative 199,125 $0.00 Strike: $3.02 $0.00
Disclosure

SEC source: 0001104659-24-004545 · tm243529-4_4seq1.xml · derivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,125

Underlying: Common Stock · 199,125 shares

Expires 2034-01-14

F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over four years from the date of grant.

Read SEC document
October 02, 2023 Filed Oct 4, 2023 20:31 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantStock Option (right to buy) · Derivative 9,102 $0.00 Strike: $1.26 $0.00
Disclosure

SEC source: 0001104659-23-106843 · tm2327613-5_4seq1.xml · derivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,102

Underlying: Common Stock · 9,102 shares

Expires 2033-10-01

F1 · shares: This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for non-employee director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $9,557.69 for service as a non-employee director between July 1, 2023 and September 10, 2023 in the quarter ended September 30, 2023.

F2 · derivative.exercise_date: Fully vested as of the date of grant.

Read SEC document
September 11, 2023 Filed Sep 13, 2023 20:01 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantRestricted stock unit · Derivative 667,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-23-100441 · tm2326002-1_4seq1.xml · derivative · entry 2

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 667,000

Underlying: Common Stock · 667,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Common Stock of the Issuer.

F3 · derivative.exercise_date: The RSUs shall vest in equal annual installments over four years from the date of grant, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

F3 · derivative.expiration_date: The RSUs shall vest in equal annual installments over four years from the date of grant, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
September 11, 2023 Filed Sep 13, 2023 20:01 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantStock option (right to buy) · Derivative 1,000,000 $0.00 Strike: $1.32 $0.00
Disclosure

SEC source: 0001104659-23-100441 · tm2326002-1_4seq1.xml · derivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2033-09-10

F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on the first anniversary of the grant, and the remainder shall vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
August 16, 2023 Filed Aug 19, 2023 00:30 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 GrantStock Option (right to buy) · Derivative 136,500 $0.00 Strike: $2.79 $0.00
Disclosure

SEC source: 0001415889-23-012415 · form4-08182023_080801.xml · derivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · PRESIDENT AND HEAD OF R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,500

Underlying: Common Stock · 136,500 shares

Expires 2033-08-15

F1 · derivative.exercise_date: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date.

Read SEC document
July 03, 2023 Filed Jul 6, 2023 20:23 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantStock Option (right to buy) · Derivative 4,477 $0.00 Strike: $3.42 $0.00
Disclosure

SEC source: 0001104659-23-078752 · tm2320657-3_4seq1.xml · derivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,477

Underlying: Common Stock · 4,477 shares

Expires 2033-07-02

F1 · shares: This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $12,250 for the quarter ended June 30, 2023.

F2 · derivative.exercise_date: Fully vested as of the date of grant.

Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:16 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantStock Option (right to buy) · Derivative 18,355 $0.00 Strike: $8.64 $0.00
Disclosure

SEC source: 0001104659-23-070362 · tm2318463-4_4seq1.xml · derivative · entry 2

Huber Martin H. Jr. · CIK 0001653276 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,355

Underlying: Common Stock · 18,355 shares

Expires 2033-06-07

F2 · derivative.exercise_date: The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date.

Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:16 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantCommon Stock 14,467 $0.00 $0.00
Disclosure

SEC source: 0001104659-23-070362 · tm2318463-4_4seq1.xml · nonDerivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,467

F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents the contingent right to receive one share of Common Stock of the Issuer.

F2 · shares: The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date.

Read SEC document
April 03, 2023 Filed Apr 5, 2023 21:15 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantStock Option (right to buy) · Derivative 3,375 $0.00 Strike: $4.25 $0.00
Disclosure

SEC source: 0001104659-23-042244 · tm2311858-4_4seq1.xml · derivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,375

Underlying: Common Stock · 3,375 shares

Expires 2033-04-02

F1 · shares: This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $11,000 for the quarter ended March 31, 2023.

F2 · derivative.exercise_date: Fully vested as of the date of grant

Read SEC document
February 02, 2023 Filed Feb 3, 2023 21:56 UTC Syndax Pharmaceuticals Inc SNDX · Entity 4578 GrantCommon Stock 16,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000946 · primarydocument.xml · nonDerivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Read SEC document
January 01, 2023 Filed Jan 4, 2023 21:11 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 GrantStock Option (right to buy) · Derivative 136,500 $0.00 Strike: $2.69 $0.00
Disclosure

SEC source: 0001415889-23-000289 · form4-01042023_090139.xml · derivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · PRESIDENT AND HEAD OF R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,500

Underlying: Common Stock · 136,500 shares

Expires 2032-12-31

F1 · derivative.exercise_date: The option award was granted on January 1, 2023 and shall vest on February 1, 2023 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until January 1, 2027.

Read SEC document
June 15, 2022 Filed Jun 17, 2022 20:31 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 GrantStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $2.28 $0.00
Disclosure

SEC source: 0001415889-22-006747 · form4-06172022_040644.xml · derivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · PRESIDENT AND HEAD OF R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The option award was granted on June 15, 2022 and will vest in equal monthly installments until June 15, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
June 15, 2022 Filed Jun 23, 2022 23:30 UTC Amendment Xilio Therapeutics, Inc. XLO · Entity 7122 GrantStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $2.28 $0.00
Disclosure

SEC source: 0001415889-22-006908 · form4a-06232022_070602.xml · derivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · PRESIDENT AND HEAD OF R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The option award was granted on June 15, 2022 and shall vest on July 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until June 1, 2026.

Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:18 UTC Mersana Therapeutics, Inc. MRSN · Entity 69982 GrantStock Option (right to buy) · Derivative 45,000 $0.00 Strike: $3.62 $0.00
Disclosure

SEC source: 0001104659-22-070138 · tm2218135-2_4seq1.xml · derivative · entry 1

Huber Martin H. Jr. · CIK 0001653276 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2032-06-08

F1 · derivative.exercise_date: The option will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders of Mersana Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.